Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature | Genetics and Genomics | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
Testa  JR, Cheung  M, Pei  J,  et al.  Germline BAP1 mutations predispose to malignant mesothelioma.  Nat Genet. 2011;43(10):1022-1025.PubMedGoogle ScholarCrossref
2.
Wiesner  T, Obenauf  AC, Murali  R,  et al.  Germline mutations in BAP1 predispose to melanocytic tumors.  Nat Genet. 2011;43(10):1018-1021.PubMedGoogle ScholarCrossref
3.
Abdel-Rahman  MH, Pilarski  R, Cebulla  CM,  et al.  Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers.  J Med Genet. 2011;48(12):856-859.PubMedGoogle ScholarCrossref
4.
Popova  T, Hebert  L, Jacquemin  V,  et al.  Germline BAP1 mutations predispose to renal cell carcinomas.  Am J Hum Genet. 2013;92(6):974-980.PubMedGoogle ScholarCrossref
5.
Farley  MN, Schmidt  LS, Mester  JL,  et al.  A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.  Mol Cancer Res. 2013;11(9):1061-1071.PubMedGoogle ScholarCrossref
6.
Cheung  M, Talarchek  J, Schindeler  K,  et al.  Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma.  Cancer Genet. 2013;206(5):206-210.PubMedGoogle ScholarCrossref
7.
Wadt  KA, Aoude  LG, Johansson  P,  et al.  A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma.  Clin Genet. 2015;88(3):267-272.PubMedGoogle ScholarCrossref
8.
de la Fouchardière  A, Cabaret  O, Pètre  J,  et al.  Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome.  Acta Neuropathol. 2015;129(6):921-923.PubMedGoogle ScholarCrossref
9.
McDonnell  KJ, Gallanis  GT, Heller  KA,  et al.  A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer.  Cancer Genet. 2016;209(3):75-81.PubMedGoogle ScholarCrossref
10.
Carbone  M, Ferris  LK, Baumann  F,  et al.  BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs.  J Transl Med. 2012;10:179.PubMedGoogle ScholarCrossref
11.
Rittié  L, Fisher  GJ.  Isolation and culture of skin fibroblasts.  Methods Mol Med. 2005;117:83-98.PubMedGoogle Scholar
12.
Carbone  M, Flores  EG, Emi  M,  et al.  Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s.  PLoS Genet. 2015;11(12):e1005633.PubMedGoogle ScholarCrossref
13.
Ohar  JA, Cheung  M, Talarchek  J,  et al.  Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer.  Cancer Res. 2016;76(2):206-215.PubMedGoogle ScholarCrossref
14.
Cebulla  CM, Binkley  EM, Pilarski  R,  et al.  Analysis of BAP1 germline gene mutation in young uveal melanoma patients.  Ophthalmic Genet. 2015;36(2):126-131.PubMedGoogle ScholarCrossref
15.
Howlader  N, Noone  AM, Krapcho  M,  et al. National Cancer Institute. Bethesda, MD. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). https://seer.cancer.gov/archive/csr/1975_2009_pops09/. Accessed June 19, 2017.
16.
Ludgate  MW, Fullen  DR, Lee  J,  et al.  The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution.  Cancer. 2009;115(3):631-641.PubMedGoogle ScholarCrossref
17.
Verkouteren  JA, Smedinga  H, Steyerberg  EW, Hofman  A, Nijsten  T.  Predicting the risk of a second basal cell carcinoma.  J Invest Dermatol. 2015;135(11):2649-2656.PubMedGoogle ScholarCrossref
18.
Njauw  CN, Kim  I, Piris  A,  et al.  Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families.  PLoS One. 2012;7(4):e35295.PubMedGoogle ScholarCrossref
19.
Wiesner  T, Fried  I, Ulz  P,  et al.  Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations.  J Clin Oncol. 2012;30(32):e337-e340.PubMedGoogle ScholarCrossref
20.
Rai  K, Pilarski  R, Cebulla  CM, Abdel-Rahman  MH.  Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.  Clin Genet. 2016;89(3):285-294.PubMedGoogle ScholarCrossref
21.
Aoude  LG, Gartside  M, Johansson  P,  et al.  Prevalence of germline BAP1, CDKN2A, and CDK4 mutations in an Australian population-based sample of cutaneous melanoma cases.  Twin Res Hum Genet. 2015;18(2):126-133.PubMedGoogle ScholarCrossref
22.
Gerami  P, Yélamos  O, Lee  CY,  et al.  Multiple cutaneous melanomas and clinically atypical moles in a patient with a novel germline BAP1 mutation.  JAMA Dermatol. 2015;151(11):1235-1239.PubMedGoogle ScholarCrossref
23.
Klebe  S, Driml  J, Nasu  M,  et al.  BAP1 hereditary cancer predisposition syndrome: a case report and review of literature.  Biomark Res. 2015;3:14.PubMedGoogle ScholarCrossref
24.
Harbour  JW, Onken  MD, Roberson  ED,  et al Frequent mutation of BAP1 in metastasizing uveal melanomas.  Science. 2010;330(600):1410-1413.
25.
Cheung  M, Kadariya  Y, Talarchek  J,  et al.  Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.  Cancer Lett. 2015;369(2):261-265.PubMedGoogle ScholarCrossref
26.
Wadt  K, Choi  J, Chung  JY,  et al.  A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma.  Pigment Cell Melanoma Res. 2012;25(6):815-818.PubMedGoogle ScholarCrossref
27.
Höiom  V, Edsgärd  D, Helgadottir  H,  et al.  Hereditary uveal melanoma: a report of a germline mutation in BAP1.  Genes Chromosomes Cancer. 2013;52(4):378-384.PubMedGoogle ScholarCrossref
28.
Busam  KJ, Wanna  M, Wiesner  T.  Multiple epithelioid Spitz nevi or tumors with loss of BAP1 expression: a clue to a hereditary tumor syndrome.  JAMA Dermatol. 2013;149(3):335-339.PubMedGoogle ScholarCrossref
29.
Ribeiro  C, Campelos  S, Moura  CS, Machado  JC, Justino  A, Parente  B.  Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.  Ann Oncol. 2013;24(8):2147-2150.PubMedGoogle ScholarCrossref
30.
Aoude  LG, Wadt  K, Bojesen  A,  et al.  A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers.  PLoS One. 2013;8(8):e72144.PubMedGoogle ScholarCrossref
31.
Gossage  L, Murtaza  M, Slatter  AF,  et al.  Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.  Genes Chromosomes Cancer. 2014;53(1):38-51.PubMedGoogle ScholarCrossref
32.
Maerker  DA, Zeschnigk  M, Nelles  J,  et al.  BAP1 germline mutation in two first grade family members with uveal melanoma.  Br J Ophthalmol. 2014;98(2):224-227.PubMedGoogle ScholarCrossref
33.
Pilarski  R, Cebulla  CM, Massengill  JB,  et al.  Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases.  Genes Chromosomes Cancer. 2014;53(2):177-182.PubMedGoogle ScholarCrossref
34.
Betti  M, Casalone  E, Ferrante  D,  et al.  Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.  Genes Chromosomes Cancer. 2015;54(1):51-62.PubMedGoogle ScholarCrossref
35.
Betti  M, Aspesi  A, Biasi  A,  et al.  CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.  Cancer Lett. 2016;378(2):120-130.PubMedGoogle ScholarCrossref
36.
Gupta  MP, Lane  AM, DeAngelis  MM,  et al.  Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations.  JAMA Ophthalmol. 2015;133(8):881-887.PubMedGoogle ScholarCrossref
37.
Turunen  JA, Markkinen  S, Wilska  R,  et al.  BAP1 germline mutations in Finnish patients with uveal melanoma.  Ophthalmology. 2016;123(5):1112-1117.PubMedGoogle ScholarCrossref
38.
Aoude  LG, Vajdic  CM, Kricker  A, Armstrong  B, Hayward  NK.  Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases.  Pigment Cell Melanoma Res. 2013;26(2):278-279.PubMedGoogle ScholarCrossref
39.
Guénard  F, Durocher  F.  BAP1 (BRCA1 associated protein-1 [ubiquitin carboxy-terminal hydrolase]).  Atlas Genet Cytogenet Oncol Haematol. 2010;14(7):670-672.Google Scholar
40.
Lek  M, Karczewski  KJ, Minikel  EV,  et al; Exome Aggregation Consortium.  Analysis of protein-coding genetic variation in 60,706 humans.  Nature. 2016;536(7616):285-291.PubMedGoogle ScholarCrossref
41.
Bhattacharya  S, Hanpude  P, Maiti  TK.  Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: a new insight in enzymatic inactivation.  Sci Rep. 2015;5:18462.PubMedGoogle ScholarCrossref
42.
Bononi  A, Napolitano  A, Pass  HI, Yang  H, Carbone  M.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.  Expert Rev Respir Med. 2015;9(5):633-654.PubMedGoogle ScholarCrossref
43.
Choe  N, Tanaka  S, Kagan  E.  Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells.  Am J Respir Cell Mol Biol. 1998;19(2):226-236.PubMedGoogle ScholarCrossref
44.
Huang  SX, Jaurand  MC, Kamp  DW, Whysner  J, Hei  TK.  Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.  J Toxicol Environ Health B Crit Rev. 2011;14(1-4):179-245.PubMedGoogle ScholarCrossref
45.
Baumann  F, Flores  E, Napolitano  A,  et al.  Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.  Carcinogenesis. 2015;36(1):76-81.PubMedGoogle ScholarCrossref
46.
Eletr  ZM, Yin  L, Wilkinson  KD.  BAP1 is phosphorylated at serine 592 in S-phase following DNA damage.  FEBS Lett. 2013;587(24):3906-3911.PubMedGoogle ScholarCrossref
47.
Scheuermann  JC, de Ayala Alonso  AG, Oktaba  K,  et al.  Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB.  Nature. 2010;465(7295):243-247.PubMedGoogle ScholarCrossref
48.
Yu  H, Pak  H, Hammond-Martel  I,  et al.  Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair.  Proc Natl Acad Sci U S A. 2014;111(1):285-290.PubMedGoogle ScholarCrossref
49.
Pilarski  R, Rai  K, Cebulla  C, Abdel-Rahman  M. BAP1 Tumor Predisposition Syndrome. In: Pagon  RA, Adam  MP, Ardinger  HH,  et al, eds.  GeneReviews. [Internet] Seattle, WA: University of Washington, Seattle; 2016 Oct 13:1993-2017. http://www.ncbi.nlm.nih.gov/books/NBK390611/. Accessed June 19, 2017.
50.
Carbone  M, Kanodia  S, Chao  A,  et al.  Consensus Report of the 2015 Weinman International Conference on Mesothelioma.  J Thorac Oncol. 2016;11(8):1246-1262.PubMedGoogle ScholarCrossref
Original Investigation
October 2017

Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature

Author Affiliations
  • 1Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
  • 2Massachusetts General Hospital Cancer Center, Boston
  • 3Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Boston
  • 4Department of Dermatology, University of Iowa Hospitals and Clinics, and Iowa City VAMC, Iowa City
  • 5Dana Farber Cancer Institute, Boston, Massachusettss
  • 6Section of Dermatology, University of Chicago Medicine, Chicago, Illinois
  • 7The Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois
JAMA Dermatol. 2017;153(10):999-1006. doi:10.1001/jamadermatol.2017.2330
Key Points

Question  How are patients with germline mutations in BAP1 most likely to present, and how are dermatologists involved in their care?

Findings  Among the 10 patients presented in this series, as well as the additional 205 patients identified in a review of the literature, melanocytic BAP1–mutated atypical intradermal tumors (MBAITs) had a significantly earlier median age of onset (32 years) compared with other BAP1-associated tumors and were present in 40 of 53 patients (75%) with documented skin examinations.

Meaning  Dermatologists play a crucial role in identifying patients with the BAP1 syndrome by screening patients diagnosed with MBAITs.

Abstract

Importance  Patients with germline mutations in BAP1 may develop several flesh-colored melanocytic BAP1–mutated atypical intradermal tumors (MBAITs). These tumors generally develop earlier than other BAP1–associated tumors, highlighting an important role for dermatologists in identifying and screening patients with a history suggestive of a germline mutation.

Objective  To describe 8 new families with germline mutations in BAP1 and provide a comprehensive review of reported cases.

Design, Settings and Participants  Patients were identified in an outpatient dermatology clinical setting over a 6-month period (10 mutation carriers from 8 families) and through a literature review using PubMed (205 patients).

Exposures  Mutations were identified through next-generation sequencing of saliva or blood samples, and RNA was extracted from fibroblasts cultured from a patient with an intronic variant to determine the impact of the mutation on the coding sequence.

Main Outcomes and Measures  All 215 patients were assessed for personal and/or family history and genotype. These findings were compiled and assessed for any association between genotype and phenotype.

Results  Overall, this study included 215 patients (108 women, 91 men, and 16 gender unspecified; median [range] age, 46.5 [10.0-79.0] years). Nine of the 10 patients who were identified in the outpatient dermatology setting were found to have MBAITs on clinical examination. Forty of 53 patients (75%) identified in the literature review who underwent total-body skin examinations (TBSE) were found to have MBAITs, suggesting a high penetrance in patients who have undergone TBSE. The most prevalent malignancies among BAP1 mutation carriers were uveal melanoma (n =  60 [28%]), mesothelioma (n = 48 [22%]), cutaneous melanoma (n = 38 [18%]), and renal cell carcinoma (n = 20 [9%]). A total of 71 unique mutations in BAP1 have been reported.

Conclusions and Relevance  Our results indicate that germline mutations in both coding and noncoding regions throughout the BAP1 gene can impair protein function, leading to an increased risk for several associated malignancies. Four of the 8 probands we present had no history of BAP1-associated malignancies and were assessed for germline mutations when found to have MBAITs on dermatologic examination. Dermatologists can identify patients with a high likelihood of the BAP1 cancer syndrome through personal and family history and TBSE for the presence of possible MBAITs.

×